A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
A Phase Ib/II multicentre open label study of bemcentinib (BGB324) as a single agent in
participants with Acute Myeloid Leukemia (AML) or Myelodysplastic syndrome (MDS) or in a
combination with cytarabine or decitabine in AML participants.
Bemcentinib is a potent selective small molecule inhibitor of Axl, a surface membrane protein
kinase receptor which is overexpressed in up to half of AML cases.